SAVID-SLDNCT07530419
Samsung S-Viscosity vs Canon Dispersion Slope in Steatotic Liver Disease (SAVID-SLD)
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 14 words Show 7 more changesShow less
- Trial status changed: Not Yet Recruiting → Active, Not Recruiting
- Primary completion moved earlier from Dec 30, 2026 to Oct 7, 2026
- Study completion pushed from Feb 28, 2027 to Dec 30, 2027
- Start date changed from estimate of Apr 10, 2026 to Apr 24, 2026
- Secondary endpoints: details revised at 1 of 5 entries
- Study description revised
- Publications: details revised at 1 of 1 entry
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Secondary (5)
Arms and interventions
Adult living-donor candidates undergoing donor evaluation at SNUH. Confirmed hepatic steatosis \<5%, normal AST/ALT, and absence of chronic liver disease. Participation does not affect donor candidacy decisions.
Adults with sonographically suspected or confirmed hepatic steatosis classified post-hoc as low MASH risk by satisfying ALL three criteria: LSM \<6.82 kPa AND DeepUSFF \<7.86% (\<S1) AND AST ≤40 U/L (institutional ULN).
Adults with sonographically suspected or confirmed hepatic steatosis classified post-hoc as at-risk MASH by satisfying mandatory LSM ≥6.82 kPa (suggestive of ≥F2 significant fibrosis) AND at least one of: DeepUSFF ≥15.05% (≥S2) OR AST \>40 U/L. Participants meeting neither Cohort B nor Cohort C definitions are classified as 'Indeterminate' and analyzed as an exploratory subgroup.
Adults with sonographically suspected or confirmed hepatic steatosis who do not meet the full criteria for either Cohort B (Low MASH risk) or Cohort C (At-risk MASH). This cohort primarily includes participants with DeepUSFF values in the S1 range (7.86% to \<15.05%), or those meeting only a subset of the Cohort B/C criteria. Cohort D is analyzed as a pre-specified exploratory subgroup and is not included in the primary stratified comparison between Cohort B and Cohort C. Descriptive statistics are reported separately.
Devices: Samsung Medison HERA W12 (R30) with S-Shearwave platform, Canon Aplio i800 with Dispersion Slope Imaging
Sites
1 site in 1 country
- Seoul National University HospitalSeoul, South Korea